Genetic analysis in cardiovascular disease: A clinical perspective

Cardiology in Review

Volumn 19, Issue 2, 2011, Pages 81-89

  Ho, Edwin ^a   Bhindi, Ravinay ^a   Ashley, Euan A ^b   Figtree, Gemma A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; genetic analysis

Indexed keywords

CLOPIDOGREL; UNTRANSLATED RNA; WARFARIN;

BLEEDING; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; FAMILY HISTORY; GENE LOCUS; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC TRAIT; GENETIC VARIABILITY; GENOME; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LOW DRUG DOSE; MAJOR GENE; MEDICOLEGAL ASPECT; PHARMACOGENETICS; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; AUSTRALIA; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; GENETIC VARIATION; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 79951606154     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318207ffac     Document Type: Review

References (80)

1. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet. 2001;27:234-236. (Pubitemid 32201838)
2. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants ofclinical disease expression. Nat Clin Pract Cardiovasc Med. 2008;5:158-168.
3. Wang L, Seidman JG, Seidman CE. Narrative review: harnessing molecular genetics for the diagnosis and management ofhypertrophic cardiomyopathy. Ann Intern Med. 2010;152:513-520.
4. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications ofgenetic testing for hypertrophic cardiomyopathy. JAm Coll Cardiol. 2009;54:201-211.
5. Gene Dx Inc. Cardiology Genetics Testing Services. Gene Dx Inc;2010. Available at: http://www.genedx.com/site/cardiology-genetic-testing-services. Accessed March 28, 2010.
6. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. JAm Coll Cardiol. 2007;50:1813-1821. (Pubitemid 350007965)
7. Bhuiyan ZA, Jongbloed JD, van der Smagt J, et al. Desmoglein-2 and desmocollin-2 mutations in Dutch arrhythmogenic right ventricular dysplasia/cardiomypathy patients: results from a multicenter study. Circ Cardiovasc Genet. 2009;2:418-427.
8. den Haan AD, Tan BY, Zikusoka MN, et al. Comprehensive desmosome mutation analysis in north Americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet. 2009;2:428-435.
9. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyop-athy. Nat Genet. 2004;36:1162-1164. (Pubitemid 41288964)
10. Merner ND, Hodgkinson KA, Haywood AF, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet. 2008;82:809-821.
11. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet. 2010;375:752-762.
12. Towbin JA, Bowles NE. The failing heart. Nature. 2002;415:227-233. (Pubitemid 34059529)
13. Hershberger RE, Norton N, Morales A, et al. Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet. 2010;3:155-161.
14. Priori SG. Inherited arrhythmogenic diseases: the complexity beyond mono-genic disorders. Circ Res. 2004;94:140-145. (Pubitemid 38197445)
15. Perez MV, Wheeler M, Ho M, et al. Genetics of arrhythmia: disease pathways beyond ion channels. JCardiovasc Transl Res. 2008;1:155-165.
16. Judge DP, Johnson NM. Genetic evaluation of familial cardiomyopathy. JCardiovasc Transl Res. 2008;1:144-154.
17. Myers RH, Kiely DK, Cupples LA, et al. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J. 1990;120:963-969. (Pubitemid 20346165)
18. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study ofparents and offspring. JAMA. 2004;291:2204-2211. (Pubitemid 38608169)
19. Finishing the euchromatic sequence of the human genome. Nature. 2004;431: 931-945.
20. A haplotype map ofthe human genome. Nature. 2005;437:1299-1320.
21. Peltonen L, McKusick VA. Genomics and medicine. Dissecting human disease in the postgenomic era. Science. 2001;291:1224-1229. (Pubitemid 32173078)
22. Vosberg HP. Identification of gene defects by linkage analysis: use in inherited cardiomyopathies. Eur Heart J. 1994;15(suppl D):20-23.
23. Leppert MF, Hasstedt SJ, Holm T, et al. A DNA probe for the LDL receptor gene is tightly linked to hypercholesterolemia in a pedigree with early coronary disease. Am JHum Genet. 1986;39:300-306. (Pubitemid 17170832)
24. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-239. (Pubitemid 38282747)
25. Risch NJ. Searching for genetic determinants in the new millennium. Nature. 2000;405:847-856. (Pubitemid 30407863)
26. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141:137-147. (Pubitemid 38937836)
27. Arroyo-Espliguero R, Avanzas P, Jeffery S, et al. CD14 and toll-like receptor 4: a link between infection and acute coronary events? Heart. 2004;90:983-988. (Pubitemid 39127904)
28. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role ofToll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest. 2004;34:328-334. (Pubitemid 38748072)
29. Arnett DK, Baird AE, Barkley RA, et al. Relevance ofgenetics and genomics for prevention and treatment ofcardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Inter-disciplinaryWorking Group. Circulation. 2007;115:2878-2901. (Pubitemid 46869676)
30. Watkins H, Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet. 2006;7:163-173. (Pubitemid 43361528)
31. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516-1517. (Pubitemid 26301653)
32. Wang WY, Barratt BJ, Clayton DG, et al. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet. 2005;6:109-118. (Pubitemid 40179533)
33. Kraft P, Cox DG. Study designs for genome-wide association studies. Adv Genet. 2008;60:465-504.
34. Marchini J, Cardon LR, Phillips MS, et al. The effects of human population structure on large genetic association studies. Nat Genet. 2004;36:512-517. (Pubitemid 38620038)
35. Andreasen CH, Andersen G. Gene-environment interactions and obesity-further aspects ofgenomewide association studies. Nutrition. 2009;25:998-1003.
36. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002;32:650-654. (Pubitemid 35435179)
37. Iwanaga Y, Ono K, Takagi S, et al. Association analysis between polymor-phisms of the lymphotoxin-alpha gene and myocardial infarction in a Japa-nese population. Atherosclerosis. 2004;172:197-198. (Pubitemid 38058622)
38. A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. Eur J Hum Genet. 2004;12:770-774.
39. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316: 1488-1491. (Pubitemid 46906617)
40. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk ofmyocardial infarction. Science. 2007; 316:1491-1493. (Pubitemid 46906618)
41. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443-453. (Pubitemid 47204873)
42. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature. 2007;447:661-678.
43. Roberts R. A customized genetic approach to the number one killer: coronary artery disease. Curr Opin Cardiol. 2008;23:629-633.
44. Schunkert H, Gotz A, Braund P, et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation. 2008;117:1675-684. (Pubitemid 351482592)
45. Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217-224. (Pubitemid 351171400)
46. Matarin M, Brown WM, Singleton A, et al. Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke. 2008;39:1586-1589.
47. Broadbent HM, Peden JF, Lorkowski S, et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet. 2008;17:806-814. (Pubitemid 351359697)
48. Manolio TA, Brooks LD, Collins FS. A HapMap harvest ofinsights into the genetics of common disease. J Clin Invest. 2008;118:1590-1605. (Pubitemid 351632361)
49. Schunkert H, Erdmann J, Samani NJ. Genetics of myocardial infarction: a progress report. Eur Heart J. 2010;31:918-925.
50. Wallace C, Newhouse SJ, Braund P, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am JHum Genet. 2008;82:139-149. (Pubitemid 351735954)
51. Sandhu MS, Waterworth DM, Debenham SL, et al. LDL-cholesterol concen-trations: a genome-wide association study. Lancet. 2008;371:483-491. (Pubitemid 351199866)
52. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. NEngl JMed. 2009;361:2518-2528.
53. Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5:e1000504.
54. Erdmann J, Grosshennig A, Braund PS, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet. 2009;41:280-282.
55. Vasan RS, Glazer NL, Felix JF, et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA. 2009;302:168-178.
56. Chakravarti A. Population genetics-making sense out of sequence. Nat Genet. 1999;21(suppl 1):56-60. (Pubitemid 29031494)
57. Collins A, Lonjou C, Morton NE. Genetic epidemiology ofsingle-nucleotide polymorphisms. Proc Natl Acad Sci USA. 1999;96:15173-15177.
58. Janssens AC, van Duijn CM. Genome-based prediction of common diseases: methodological considerations for future research. Genome Med. 2009;1:20.
59. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol andriskofcardiovascular events. N Engl J Med. 2008;358:1240-1249. (Pubitemid 351439225)
60. Wadman M. James Watson's genome sequenced at high speed. Nature. 2008;452:788. (Pubitemid 351550830)
61. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl JMed. 2009;360:354-362.
62. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512-518.
63. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College ofCardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537-557.
64. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl JMed. 2008;359:789-799.
65. Zaiou M, Benachour H, Marteau JB, et al. Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases. Curr Pharm Des. 2009;15:3193-3206.
66. Ng SB, Buckingham KJ, Lee C, et al. Exome sequencing identifies the cause of a Mendelian disorder. Nat Genet. 2010;42:30-35.
67. Roach JC, Glusman G, Smit AF, et al. Analysis ofgenetic inheritance in a family quartet by whole-genome sequencing. Science. 2010;328:636-639.
68. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525-1535.
69. Mayer B, Erdmann J, Schunkert H. Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol. 2007;96:1-7. (Pubitemid 46175364)
70. Assmann G. Calculating global risk: the key to intervention. Eur Heart J Suppl. 2005;7(suppl F):F9-F14. (Pubitemid 43193780)
71. Scheuner MT. Genetic evaluation for coronary artery disease. Genet Med. 2003;5:269-285. (Pubitemid 36998685)
72. University ofWashington. Gene Tests. Seattle, WA: University of Washington; 2010. Available at: www.genetests.org. Accessed July 4, 2010.
73. Cirino AL, Ho CY. Genetic testing in cardiac disease: from bench to bedside. Nat Clin Pract Cardiovasc Med. 2006;3:462-463. (Pubitemid 44307825)
74. National Society of Genetic Counselors Inc. NSGC: DNA Banking. Chicago, IL: National Society of Genetic Counselors Inc; 2009. Available at: http://www.nsgc.org/dnabanking.cfm. Accessed July 4, 2010.
75. Shimizu W, Tanabe Y, Aiba T, et al. Differential effects ofbeta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. JAm Coll Cardiol. 2002;39:1984-1991. (Pubitemid 34628279)
76. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times-the Genetic Information Nondiscrimination Act of 2008. N Engl J Med. 2008; 358:2661-2663. (Pubitemid 351860857)
77. Genova Diagnostics Inc. Genovations Cardio Genomic Profile. Asheville, NC: Genova Diagnostics Inc; 2008. Available at: http://www.genovadiagnostics. com/files/profile-assets/referenced-materials/Genomics-PatientBrochure.pdf Accessed April 26, 2010.
78. Thomas SM, Hopkins MM, Brady M. Shares in the human genome\the future ofpatenting DNA. Nat Biotechnol. 2008;20:1185-1188.
79. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet. 2001;2:91-99. (Pubitemid 33674000)
80. Nuffield Council on Bioethics. The Ethics ofPatenting DNA. London, United Kingdom: Nuffield Council on Bioethics; 2002.